Peripheral neuropathy induced by microtubule-stabilizing agents

James J Lee1, Sandra M Swain

  • 1Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889-5015, USA.

Insights

Microtubule-stabilizing agents (MTSAs) effectively treat cancer but can cause severe neuropathy in up to 30% of patients. Early recognition and supportive care are crucial for managing this common chemotherapy side effect.

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Microtubule-stabilizing agents (MTSAs), such as taxanes and epothilones, are vital chemotherapeutics.
  • MTSA-based chemotherapy frequently leads to peripheral neuropathy, a significant adverse effect impacting up to 30% of patients.
  • MTSA-induced neuropathy typically resolves post-treatment but necessitates careful management.

Purpose of the Study:

  • To review the incidence, presentation, and management of microtubule-stabilizing agent-induced neuropathy.
  • To highlight the importance of clinical evaluation in assessing MTSA-induced neuropathy.
  • To identify future research directions for understanding and mitigating MTSA-induced neuropathy.

Main Methods:

  • Literature review focusing on MTSA-induced neuropathy.
  • Analysis of clinical data regarding incidence and severity.
  • Examination of current and potential assessment techniques.

Main Results:

  • Taxane-induced sensory neuropathy is the most studied form, more prevalent with paclitaxel than docetaxel.
  • Neuropathy incidence correlates with MTSA dose, treatment schedule, and infusion duration.
  • Clinical evaluation remains the gold standard for assessing MTSA-induced neuropathy.

Conclusions:

  • Early recognition and supportive care are paramount for preventing and managing MTSA-induced neuropathy.
  • Further research is needed to elucidate mechanisms, develop preclinical models, and evaluate neuroprotective agents.
  • Improved grading systems and evaluation methods are essential for future clinical trials.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Microtubule Associated Proteins (MAPs)01:42

Microtubule Associated Proteins (MAPs)

Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
Microtubule Instability02:17

Microtubule Instability

Microtubules are hollow cylindrical filaments having a diameter of approximately 25 nm and a length that varies from 200 nm to 25 μm. GTP-bound tubulin subunits form αβ-heterodimers for microtubule assembly. These core building blocks interact longitudinally, polymerizing into protofilaments. The protofilaments then interact with one another through lateral bonding forces to form stable cylindrical microtubules. These cylindrical filaments are dynamic as they undergo repeated assembly and...